Condition: Acute Myeloid Leukemia · Myelodysplastic Syndrome · Sponsor: Montefiore Medical Center
This is a Phase 1, uncontrolled, single-arm, open-label, nonrandomized, dose escalation, study of Decitabine (DAC)+Venetoclax (VEN)+FHD-286 in participants with newly diagnosed Acute Myeloid Leukemia (AML) classified as adverse risk per the 2022 European Leukemia Net (ELN) criteria or AML that has progressed after one prior line of therapy.
This description comes directly from the study's public registry record.
Mendel R Goldfinger, MD · 718-920-4826 · mgoldfin@montefiore.org
Akash R Shah · 718-862-8840 · ashah1@montefiore.org
Always discuss trial participation with your own doctor first.
| Montefiore Medical Center | The Bronx, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07283094